Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
ID: 337320Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $275K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337320

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering Exploratory/Developmental Bioengineering Research Grants (EBRG) under funding opportunity announcement PAR-22-091, aimed at stimulating innovative research in bioengineering to address biomedical challenges and enhance clinical care. This initiative encourages applications that demonstrate the feasibility and potential utility of new technologies, with grants available up to $275,000 for projects spanning two years, excluding phase III clinical trials. The program is designed to foster interdisciplinary collaborations between bioengineers and biomedical researchers, emphasizing significant medical research problems and innovative methodologies. Interested applicants, including a diverse range of organizations such as academic institutions and nonprofits, must adhere to NIH guidelines and submit their proposals by January 7, 2025. For further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-091-Full-Announcement.html
    PAR-22-091.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is offering exploratory/developmental Bioengineering Research Grants (EBRG) under funding opportunity announcement PAR-22-091. This initiative aims to stimulate innovative research in bioengineering that addresses biomedical challenges and enhances clinical care, prioritizing applications demonstrating feasibility of new technologies. Grants up to $275,000 are available for projects spanning two years, with no phase III clinical trials accepted. Key dates for submission span from January 2022 until early 2025, with ongoing opportunities to submit resubmission or revision applications. Eligible applicants include a wide range of organizations—academic institutions, nonprofits, for-profits, and international entities. A detailed application process requires adherence to NIH guidelines, including data management and sharing plans. Research proposals should emphasize significant problems in medical research or clinical practice, innovative approaches, and a well-structured methodology. Applications will undergo peer review focusing on scientific merit and potential impact, with special consideration for those that involve collaborations between bioengineers and biomedical researchers. This funding initiative is part of a broader effort to foster interdisciplinary projects that can lead to transformative advancements in healthcare delivery.
    Similar Opportunities
    Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced the Exploratory/Developmental Bioengineering Research Grants (EBRG) under the R21 funding mechanism, aimed at fostering innovative projects that address significant biomedical challenges. This funding opportunity encourages applications that explore new capabilities or improvements in biomedical research, clinical care delivery, and accessibility, with a focus on groundbreaking engineering research and collaboration across diverse scientific disciplines. Eligible applicants include higher education institutions, nonprofits, and small businesses, with a budget cap of $275,000 over two years, and applications are due by January 7, 2025. For further inquiries, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-22-091.html.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the Bioengineering Research Grants (BRG), aimed at fostering multidisciplinary collaborations to address significant biomedical challenges. This funding opportunity encourages innovative research that integrates life and physical sciences to develop tools, methods, and technologies that can enhance healthcare delivery and medical practices. Eligible applicants include a diverse range of institutions, such as historically black colleges, tribal colleges, and community-based organizations, with projects allowed to span up to five years under the R01 grant mechanism. Interested parties should submit their applications electronically by September 7, 2025, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov.
    Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering Bioengineering Research Grants (BRG) to encourage multidisciplinary collaborations that address significant biomedical challenges through innovative technologies. This funding opportunity aims to integrate life and physical sciences to accelerate the adoption of promising tools and methods in clinical or translational science, with a focus on projects that may involve clinical trials assessing functionality or performance in real-world settings. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and foreign entities, with no cost-sharing requirement, and applications are due by September 7, 2025. For more information, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the official announcement at https://grants.nih.gov/grants/guide/pa-files/PAR-22-243.html.
    Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)" aimed at fostering collaborative research between academic institutions and industrial partners to accelerate the development of innovative bioengineering tools addressing critical biomedical challenges. This initiative seeks multidisciplinary teams that integrate engineering principles to create robust solutions capable of enhancing life sciences understanding and medical practices within a 5-10 year timeframe. The program emphasizes the importance of partnerships in overcoming development barriers and facilitating technology validation and commercialization, ultimately aiming to improve patient health outcomes. Interested applicants can find more details and submit inquiries via the NIH OER Webmaster at OERWebmaster03@od.nih.gov, with applications due by January 7, 2025.
    Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Team-Based Design in Biomedical Engineering Education (R25 Clinical Trial Not Allowed)" aimed at enhancing biomedical engineering education through innovative team-based design courses. This initiative seeks to support educational programs that prepare undergraduate students in biomedical engineering/bioengineering fields to meet national biomedical needs, with a focus on promoting health equity and universal design. Institutions can apply for grants of up to $40,000 per year for projects lasting up to five years, with a submission deadline of January 30, 2025. Interested applicants should ensure compliance with eligibility criteria and submit detailed proposals that include innovative educational plans and collaborations with relevant disciplines; for further inquiries, contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    National Centers for Biomedical Imaging and Bioengineering (NCBIB) (P41 Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "National Centers for Biomedical Imaging and Bioengineering (NCBIB)" aimed at supporting the development and dissemination of new biomedical technologies. This initiative encourages applications from a diverse range of eligible entities, including higher education institutions and nonprofit organizations, to conduct technology research and development projects, collaborative projects, and service projects that address biomedical challenges. The program is designed to foster innovative research and enhance clinical applications, with funding typically ranging from $600,000 to $750,000 per project, and awards may last up to five years, with a total funding cap of fifteen years for any Center. Interested applicants should note that the application process opens on September 25, 2023, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov. For more details, please refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-23-235.html.
    Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs) (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Enhancing Biomedical Engineering, Imaging, and Technology Acceleration (BEITA) at Historically Black Colleges and Universities (HBCUs)." This initiative aims to enhance research capacity, technology innovation, and educational opportunities in biomedical engineering and related fields at HBCUs through a two-phase funding approach, with Phase I (UG3) offering up to $300,000 annually for planning and Phase II (UH3) allowing for up to $1,000,000 per year for full-scale program implementation. The program emphasizes the importance of diversity in the scientific workforce and seeks to leverage HBCUs' talent to address health disparities in the U.S. Interested applicants must submit their proposals by September 30, 2025, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed) to support innovative biomedical and clinical research projects. This grant aims to foster exploratory research that may involve significant risks but has the potential for breakthroughs or the development of novel methodologies in health-related fields. The program is crucial for advancing research that addresses pressing health challenges and encourages applications that present new scientific ideas distinct from traditional R01 projects. Eligible applicants include a wide range of institutions, including higher education institutions, nonprofits, and for-profit organizations, both domestic and foreign, with a budget limit of $275,000 over two years and a maximum request of $200,000 in any single year. Interested parties should submit their applications electronically by January 7, 2025, and can contact the NIH OER Webmaster at FBOWebmaster@OD.NIH.GOV for further assistance.
    Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled “Technology Development Research for Establishing Feasibility and Proof of Concept (R21 - Clinical Trial Not Allowed),” aimed at supporting exploratory research for innovative biomedical technologies. This initiative focuses on high-risk projects that have not yet established feasibility, specifically targeting the development of tools such as laboratory instruments, algorithms, and chemical reagents, while excluding applications that address specific biological questions or present existing proof of concept data. Eligible applicants can request funding of up to $275,000 over two years, with a maximum of $200,000 in any single year, and applications are due by May 7, 2025. For further details, interested parties can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov or refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-126.html.
    Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Research on Bioethical Issues Related to Bionic and Robotic Device Development and Translation" (R21 Clinical Trial Optional). This initiative aims to support research that addresses ethical questions throughout the design, testing, and implementation phases of bionic and robotic devices, focusing on issues such as autonomy, informed consent, and equitable access to technology. A total of $2 million is available to fund 4-5 awards, with each project budget capped at $275,000 over two years. Interested applicants must submit their proposals by January 26, 2024, and can find additional details and guidelines at the NIH grants website or by contacting grantsinfo@nih.gov.